ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Saved in:
Bibliographic Details
Title: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.
Authors: Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Yao Y; Blood Diseases Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China., Perini T; Laboratory of Age Related Diseases, Division of Genetics and Cell Biology and Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Fong Ng J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schavgoulidze A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Cui J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Encinas Mayoral J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ladisa F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Young RM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Epstein CB; The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts., White CM; The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts., Ott CJ; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts., Gulla A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Matulis SM; Department of Hematology and Medical Oncology and the Winship Cancer Institute at Emory University, Atlanta, Georgia., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts., Morelli E; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute at Emory University, Atlanta, Georgia., Binder M; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Szalat R; Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, Massachusetts., Samur MK; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; VA Boston Healthcare System, Boston, Massachusetts.
Source: Blood cancer discovery [Blood Cancer Discov] 2026 Jan 12; Vol. 7 (1), pp. 129-141.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101764786 Publication Model: Print Cited Medium: Internet ISSN: 2643-3249 (Electronic) Linking ISSN: 26433230 NLM ISO Abbreviation: Blood Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2643-3249
DOI:10.1158/2643-3230.BCD-25-0048